(c) 2024 PillSync.com

mesalamine mesalamine film coated tablet delayed release

1 INDICATIONS AND USAGE Mesalamine delayed-release tablets are indicated for the: • induction and maintenance of remission in adult patients with mildly to moderately active ulcerative colitis. Pediatric use information is approved for Takeda Pharmaceuticals U.S.A., Inc.’s LIALDA (mesalamine) delayed-release tablets. However, due to Takeda Pharmaceuticals U.S.A., Inc.’s marketing exclusivity rights, this drug product is not labeled with that information. Mesalamine delayed-release tablets are an aminosalicylate indicated for the: • induction and maintenance of remission in adult patients with mildly to moderately active ulcerative colitis. ( 1 )

mylan pharmaceuticals inc.


5 years ago OVAL BROWN M1200 mesalamine mesalamine film coated tablet delayed release

OVAL BROWN M1200

5 years ago OVAL BROWN M1200 mesalamine mesalamine film coated tablet delayed release

M1200 OVAL BROWN

16 HOW SUPPLIED/STORAGE AND HANDLING Mesalamine Delayed-Release Tablets, USP are available containing 1.2 g of mesalamine, USP. The 1.2 g tablets are tan, film-coated, ellipsoidal, unscored tablets imprinted with M1200 in black ink on one side of the tablet and plain on the other side. They are available as follows: NDC 0378-7401-78 bottles of 120 tablets Store at room temperature 20° to 25° C (68° to 77° F). [See USP Controlled Room Temperature.] Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.


More pills like OVAL M1200












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site